Noa Therapeutics is a preclinical biotech company leveraging a systems biology approach to accelerate the design of tailored multimodal therapeutics for complex inflammatory diseases. With discrete expertise in dermal therapeutics, Noa is advancing a first-use case in Atopic Dermatitis. Noa’s non-steroidal lead drug compound, NOA-101, simultaneously addresses three constructive targets to address persistent unmet needs to displace multiple major players within the $5.0B, 10.1% CAGR US market, paving the way for pipeline expansion into the greater than $70B inflammatory disease markets.

Noa Therapeutics  logo



Event details

Date: June 5 - 8, 2023

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


33 in total